

MEDICAL

The MEDICAL Policy Statement detailed above has received due consideration as defined in the
MEDICAL Policy Statem

The MEDICAL Policy Statement detailed above has received due consi

E. Conditions of Coverage
 N/A

F. Related Policies/Rules
 Medical Necessity Determinations

G. Review/Revision History

	DATE	ACTION
Date Issued	06/21/2024	New Policy. Approved at committee.
Date Revised	03/13/2024	Updated reference. Approved at Committee.
Date Effective	07/01/2024	
Date Archived		

H. References

1. Andre F, Ismaila N, Allison KH, et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. *J Clin Oncol.* 2022;40(16):1816-1837. doi:10.1200/JCO.22.00069
2. Local Coverage Determination: MolDX: Breast Cancer Index® (BCI) Gene Expression Test. Medicare Coverage Database; 2023. Accessed February 28, 2024. www.cms.gov
3. Molecular Test Assessment: Breast Cancer Index (BioTheranostics Inc.) for Lymph Node–Negative Patients. Hayes; 2020. Updated December 5, 2023. Accessed February 28, 2024. www.hayesinc.com
4. Molecular Test Assessment: Breast Cancer Index (BioTheranostics Inc.) for Lymph Node–Positive (1-3) Patients. Hayes; 2020. Updated December 6, 2023. Accessed February 28, 2024. www.hayesinc.com
5. National Cancer Institute (NCI) Fact Sheet. Hormone Therapy for Breast Cancer. Accessed February 28, 2024. www.cancer.gov
6. Noodhoek I, Treuner K, Putter H, et al. Breast Cancer Index predicts extended endocrine benefit to individualize selection of patients with HR+ early-stage breast cancer for 10 years of endocrine therapy. *Clin Cancer Res.* 2021;27(1):311-319. doi:10.1158/1078-0432.CCR-20-2737
7. Optum EncoderPro for Payer Professionals. CPT code 81518. Accessed February 28, 2024. www.encoderprofp.com.
8. Sanft T, Aktas B, Schroeder B, et al. Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer. *Breast Cancer Res Treat.* 2015;154(3):533-41. doi:10.1007/s10549-015-3631-9

Approved by ODM on 3/21/2024

The MEDICAL Policy Statement detailed above has received due consideration as defined in the MEDICAL Policy Statement Policy and is approved.